Sector News

Ferring appoints Dominic Moorhead as EVP and CFO

April 4, 2017
Life sciences

Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017.

Moorhead succeeds Peter Wilden, who joined Ferring 25 years ago and was one of the original members of the Group Executive Board.

Following a three-month transition period, Moorhead will assume full responsibility for the Finance, Corporate Information Systems and Internal Audit functions of the global Ferring Group. Wilden will continue to represent Ferring on a number of additional Boards.

“Peter has been a guardian of Ferring’s financial integrity and stability, and we will look back with satisfaction on his exceptional career within the company,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer of Ferring. “I am confident that Dominic will continue this track record of success. His extensive experience and perspectives in finance, business and strategic development in the pharmaceutical sector make him a great fit for Ferring as we continue on our strong growth path.”

Moorhead has 30 years’ finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech. Before this, he worked for Takeda Pharmaceuticals for four years, as Global Financial Controller, and CFO of the International business following the acquisition of Nycomed. Prior to this he worked for Hoffmann-La Roche for 13 years, where he was CFO of the Pharma Division for nine years during a period of much challenge, transformation, and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatization of Genentech in the U.S. in 2009.

Source: Ferring Pharmaceuticals

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]